Medtronic (MDT) Granted 510(k) Clearance by FDA for LUCAS(TM) 2
More News related to MDT
- Medtronic Receives President's "E" Award in Recognition of Its Support of U.S. Exports
- Notable Analyst Rating Changes 11/5: PALM, VALE, TRW, ONNN, MDT, SPWRA Upgraded; CMCSA, ARO, DPTR, GRMN TEX Downgraded
- Credit Suisse Upgrades Medtronic (MDT) to Outperform
- Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement
- CORRECTION FROM SOURCE: Saskatchewan Roughrider John Chick Shows London Children that Diabetes Doesn't Have to Prevent Them from Reaching Their Dreams
More News related to FDA
- S&P Announces Change to US Index: LL for UCBH
- Electronic Arts (ERTS) Makes Major Job Cuts As Q2 Profits Lag
- Kraft (KFT) to Ask Holders to Vote to Issue New Shares
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced today that LUCAS(TM) 2, the next-generation LUCAS(TM) Chest Compression System, has been granted 510(k) market clearance by the U.S. FDA. Developed and manufactured by Jolife AB and distributed exclusively in the United States by Physio-Control, the LUCAS 2 is an automated, battery-powered device that is designed to give consistent, uninterrupted compressions to victims in cardiac arrest.
More from the release.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
